anti-CD19 CAR-T cell therapy / Shanghai Children's Medical Center - LARVOL DELTA

LONG-TERM FOLLOW-UP OF CAR-T THERAPY FOLLOWED BY HAPLOIDENTICAL HSCT FOR RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA: A MULTI-CENTER RETROSPECTIVE STUDY (EBMT 2025) - P=N/A | " We previously reported the results of 122 patients with r/r ALL received anti-CD19 CAR-T including 67 patients without subsequent transplantation (non-transplant group) and 55 patients with subsequent haplo-HSCT (transplant group) at a median follow-up of 20.4 months. Haploidentical hematopoietic stem cell transplantation with pre-transplant MRD negativity after CAR-T therapy could greatly improve LFS and OS in patients with relapsed/refractory acute lymphoblastic leukemia. However, infections are key survivorship issues that reduce long-term survival after CAR T-cell therapy. Clinical Trial Registry: The study was registered in the Chinese clinical trial registry (ChiCTR1900023957)."

Retrospective data • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Cardiovascular • Chronic Graft versus Host Disease • Congestive Heart Failure • Graft versus Host Disease • Heart Failure • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Oncology

CAR-Aptamers Enable Traceless Enrichment and Monitoring of CAR-Positive Cells and Overcome Tumor Immune Escape. (PubMed, Adv Sci (Weinh)) - "Chimeric antigen receptor (CAR)-positive cell therapy, specifically with anti-CD19 CAR-T (CAR19-T) cells, achieves a high complete response during tumor treatment for hematological malignancies...Overall, novel CAR-aptamers are screened for traceless enrichment, monitoring of CAR-positive cells, and overcoming tumor cell immune escape. This provides a low-cost and high-throughput approach for CAR-positive cell-based immunotherapy."

Journal • Hematological Disorders • Hematological Malignancies • Oncology • PTK7